GCCL Opens Expanded Laboratory for Clinical Trial Specimen Analysis

Expansion of Analysis Service Scope

GC Green Cross LabCell's clinical specimen analysis service subsidiary, GCCL, announced on the 13th that it has expanded and opened a second analysis laboratory for multi-center clinical trials.

GCCL is a corporation jointly established in 2019 by GC Green Cross LabCell and the contract research organization (CRO) C&R Research. It is a central lab that provides clinical specimen analysis services throughout the entire clinical trial process, from Phase 1 to approval trials. A central lab refers to an institution that collects specimens obtained before and after clinical trials from multiple hospitals into a single laboratory for testing to ensure accurate clinical trial results.

The newly expanded second laboratory is located within the GC Green Cross LabCell headquarters in Yongin, Gyeonggi Province. It covers an area of 310㎡. GCCL explained, "With the expansion of this laboratory, the latest analytical equipment and facilities have been enhanced, expanding the range of analysis services such as immunogenicity testing and immune cell analysis."

The existing first laboratory, capable of conducting over 1,000 tests including drug, biomarker, and biological sample analysis, has also been subdivided by clinical trial phase to strengthen expertise. A GCCL representative stated, "We will provide an analysis environment tailored to various clinical trial requirements to deliver top-level services," adding, "A data system to prevent clinical trial errors will also be commercialized soon."

Meanwhile, last month, GCCL obtained the international standard 'ISO 15189 accreditation,' which guarantees that various clinical-related tests meet technical requirements and reliability.

This content was produced with the assistance of AI translation services.